CHANTILLY, Va., March 8 /PRNewswire/ -- Dynex Technologies, a global supplier of microplate instrumentation and automation products for the biomedical research, drug-discovery, and clinical-diagnostic markets, announced today that Henry O'Connell has been named president, effective immediately.
"Henry brings to Dynex more than 20 years of experience in the analytical instrumentation, clinical diagnostics, and life science industries," said Robert J. Rosenthal, president and chief executive officer of parent company, Magellan Biosciences, Inc. "A dynamic leader, Henry has the right combination of skills, experience, and know-how to leverage Dynex's strong technology base to serve life-science customers better. He has an excellent track record of delivering continuous quality and operational improvements, and meeting customer needs."
O'Connell comes to Dynex from IDEX Corporation, where he was president/group executive of the Precision Flow Products Group. Prior experience included senior management positions at Promega, Inc., Gilson Inc., Groton Technologies, Upchurch Scientific, and SpectraTech Applied Systems. He started his career in the life-science industry as a research fellow focusing on genetic disease therapeutics at the National Institutes of Health (NIH).
"Dynex has excellent products, a world-class staff, and tremendous opportunities for growth," said O'Connell. "I am very excited to join the company, and over the course of the next few months, will be calling on customers to learn how we can best meet their products and services needs."
O'Connell holds a BS in biology from Wabash College, Crawfordsville, Indiana, an MS in life sciences from the University of Connecticut, and completed coursework in a PhD program in biochemistry at the University of Maryland, leaving to pursue his role at the NIH. In addition to his academic training he has completed six sigma greenbelt training.
About Dynex Technologies, Inc.
Founded in 1952, and headquartered in Chantilly, Virginia, Dynex is a leading manufacturer of products incorporating advance detection and fully automated sample handling used in clinical diagnostics, drug discovery, and biomedical research. Dynex employs approximately 50 people at its facility in Chantilly, and at European subsidiaries, Dynex Technologies Ltd and Dynex Technologies GmbH. Dynex is a wholly owned subsidiary of Magellan Biosciences For more information, visit http://www.dynextechnologies.com/.
Company Contact Media Contact
Henry O'Connell Caroline A. Grossman